Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 7/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11796831 | 0.81 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1MEN1KMT2A | |
| SCHEMBL30273 | 0.79 | — | — | |
| SCHEMBL29440543 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL9494075 | 0.77 | ALDH1A1 (0.48) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Bromide SCHEMBL7895133 | 0.77 | ALDH1A1 (0.48) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9057722 | 0.77 | ALDH1A1 (0.48) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL6344325 | 0.76 | CYP3A4 (0.39) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL10203130 | 0.76 | CYP3A4 (0.39) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL1374281 | 0.76 | CYP3A4 (0.39) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL4883677 | 0.75 | MEN1 (0.43) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275429-A2 | Method for producing a ruthenium complex | Takasago International Corporation (JP) | 2011-01-19 | — | — | EP | claimed |
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1503990-A1 | ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR | Transmit Gesellschaft für Technologietransfer mbH (DE) | 2005-02-09 | — | — | EP | claimed |
| WO-2003095429-A1 | ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR | TransMIT Gesellschaft für Technologietransfer mbH (DE) | 2003-11-20 | — | — | WO | claimed |
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) | 2005-10-27 | — | — | US | disclosed |
| EP-1503990-A1 | ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR | Transmit Gesellschaft für Technologietransfer mbH (DE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003095429-A1 | ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR | TransMIT Gesellschaft für Technologietransfer mbH (DE) | 2003-11-20 | — | — | WO | disclosed |
| US-4267252-A | AND PHOTOGRAPHIC FILMS USING THEM | POLAROID CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4267253-A | AND PHOTOGRAPHIC FILMS CONTAINING THEM | POLAROID CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4247455-A | Yellow 2:1 azo-azo or azo-azomethine chrome complexed dye developers | POLAROID CORPORATION (US) | 1981-01-27 | — | — | US | disclosed |
| US-4174221-A | AZO AND AZO-METHINE METALLIZED ANIONIC DYES FOR SELF-DEVELOPING PHOTOGRAPHIC FILMS | POLAROID CORPORATION (US) | 1979-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | PRNP, APP, MAPT | CYP3A4 2445/4885ALOX15 4708/4885CASP1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.